

# Cristina Gravalos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2030993/publications.pdf>

Version: 2024-02-01

32  
papers

1,566  
citations

643344

15  
h-index

511568

30  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	5
2	First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. <i>Drugs and Aging</i> , 2021, 38, 219-231.	1.3	3
3	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. <i>BMC Cancer</i> , 2020, 20, 1164.	1.1	7
4	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	1.0	15
5	Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 556-571.	1.2	29
6	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. <i>ESMO Open</i> , 2019, 4, e000599.	2.0	11
7	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018, 29, 439-444.	0.6	14
8	The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018, 90, 63-72.	1.3	69
9	SEOM clinical guideline for treatment of cancer pain (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 97-107.	1.2	61
10	Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2017, 19, 682-694.	1.2	2
11	SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1243-1253.	1.2	34
12	Seom guidelines for the treatment of gastric cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 996-1004.	1.2	25
13	Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 763-771.	1.2	25
14	Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 535-541.	0.6	60
15	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. <i>BMC Cancer</i> , 2015, 15, 60.	1.1	41
16	Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. <i>BMC Cancer</i> , 2015, 15, 327.	1.1	13
17	A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 606-612.	1.2	19
18	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012, 14, 820-826.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 423-429.	1.2	7
20	SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 528-535.	1.2	16
21	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 179-184.	1.2	75
22	Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 862-868.	1.2	1
23	Integration of panitumumab into the treatment of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 16-26.	2.0	24
24	The potential role of sunitinib in gastrointestinal cancers other than GIST. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 36-43.	2.0	3
25	Recommendations on current approach to gastric cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 518-525.	1.2	3
26	Adjuvant chemotherapy for stages II, III and IV of colon cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 526-533.	1.2	32
27	Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen. <i>Journal of Clinical Oncology</i> , 2009, 27, e22220-e22220.	0.8	0
28	Surgical Resection of a Solitary Pancreatic Metastasis from Colorectal Cancer: A New Step to a Cure?. <i>Clinical Colorectal Cancer</i> , 2008, 7, 398-401.	1.0	6
29	HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. <i>Annals of Oncology</i> , 2008, 19, 1523-1529.	0.6	931
30	Role of Tyrosine Kinase Inhibitors in the Treatment of Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 691-699.	1.0	28
31	TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): Preliminary results of a multicenter randomized phase II trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 3599-3599.	0.8	0
32	Phase II study of Mitonafide in advanced and relapsed colorectal cancer. <i>Investigational New Drugs</i> , 1996, 14, 223-5.	1.2	4